MECHANISMS OF ACTION

First-in-class monoclonal antibody that targets CD38

Share

CD38 is expressed on hematopoietic cells, other cell types and tissues, and is overexpressed on multiple myeloma cells1,2

DARZALEX® inhibits tumor cell growth through immune-mediated, direct on-tumor, and immunoregulatory actions. DARZALEX® may also have an effect on normal cells1

 

DARZALEX® is the first CD38-targeted monoclonal antibody (mAb)1